This inventor holds 1 USPTO granted patent. Top assignee: Janssen Pharmaceutica Nv. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Inventor Profile: Karoline Kielbassa
Introduction
Karoline Kielbassa, a talented inventor based in Amsterdam, Netherlands, has made significant contributions within the field of oncology through her innovative research and development. She is currently associated with Janssen Pharmaceutica NV, where she utilizes her expertise to advance therapeutic solutions for patients battling B-cell malignancies.
Latest Patents
Karoline Kielbassa holds one patent titled "Methods and compositions for treating B-cell malignancies." This patent focuses on methods of treating malignancies through a combination therapy. The innovative treatment involves administering a combination of an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) and an inhibitor of an anti-apoptotic Bcl-2 family protein. The approach is designed to effectively reduce malignancies in subjects while also addressing regulatory T cell levels in patients suffering from these conditions.
Career Highlights
Throughout her career, Karoline has demonstrated a commitment to advancing healthcare solutions. Her role at Janssen Pharmaceutica NV highlights her dedication to applying scientific research for patient benefit. Karoline's focus on developing effective treatments showcases her innovative spirit and determination to improve patient outcomes in oncology.
Collaborations
During her time at Janssen Pharmaceutica NV, Karoline Kielbassa has collaborated with esteemed colleagues, including Eric Frederik Eldering and Ulrike Philippar. These collaborations reflect the teamwork necessary to propel innovative research and bring groundbreaking therapies to fruition.
Conclusion
Karoline Kielbassa stands out as an influential inventor in the field of oncology. Her patent addressing treatment methods for B-cell malignancies highlights her contribution to medical research. As she continues her work at Janssen Pharmaceutica NV, her innovations hold the potential to improve the lives of many patients facing challenging health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile